7 results
To assess the analgesic effect of ARA290 in chronic pain patients
Primary Objective: To determine whether topical application of Calcitriol (Silkis) 3 µg/g, Diclofenac 10% or a combination of both can lead to a 40% histological reduction (*)/increase (*) of expression of the following antibodies: Ki67 (*), BCL2…
ARA290 is a new drug against neuropathic pain and was succesfully tested in previous studies on patients with neuropathic pain due to diabetes and sarcoidosis. The current study involves sarcoidosis patients with pain due to neuropathy. The purpose…
In this study we will assess the effect of ARA290 on nerve damage by taking 4 skin bipsies during treatment.
To measure the PK of ARA290 when given in de SQ form
To measure the plasma conc. of ARA 290 in healthy volunteers
The primary objectives of this study are to examine the clinical efficacy of nusinersen administered intrathecally at higher doses to participants with spinal muscular atrophy (SMA), as measured by change in Children's Hospital of Philadelphia…